
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
XMP.629 belongs to the BPI family of compounds ... it is able to kill gram-negative bacteria by selectively altering their outer membrane permeability.






